FDA testing plans to include blood pressure generics


The US Food and Drug Administration (FDA) is planning an extensive study of blood-pressure drugs after receiving thousands of complaints from doctors and patients. FDA has been allocated US$20 million for testing generics, with the 2014 focus being on heart drugs, attention deficit hyperactivity disorder (ADHD) treatments, immunosuppressants, anti-seizure medicines and antidepressants [1]. But due to the high number of complaints – more than 3,400 adverse reaction reports citing lack of effectiveness and side effects – FDA has expanded this to include the high blood pressure treatment metoprolol succinate.

Read the source article at gabionline.net

About the Author

Leave a Reply